CTT Pharmaceutical Holdings, Inc. has recently announced that its CEO, Ryan Khouri, acquired 9,000 shares of the company’s stock. This transaction, reported in a filing on November 6, 2026, is significant as it reflects the CEO's confidence in the company's prospects. The acquisition of shares by a high-ranking executive often signals a positive outlook, which can influence investor sentiment.

Background

CTT Pharmaceutical Holdings, Inc. operates in the pharmaceutical preparations industry, classified under the SIC code 2834. The company, which trades under the ticker CTTH on the OTC exchange, is categorized as a non-accelerated filer and an emerging growth company. CTT is based in Tampa, Florida, and has undergone several name changes in its history, previously known as Mindesta Inc., Industrial Minerals Inc., and PNW Capital Inc.

What the Filing Says

According to the filing dated November 6, 2026, Ryan Khouri acquired 9,000 shares of CTT Pharmaceutical Holdings at a price of $0.05 per share on November 4, 2026. Following this transaction, Khouri owns a total of 9,452,536 shares in the company. The filing indicates that this acquisition was a direct ownership transaction.

Impact

This stock acquisition may impact various stakeholders within the company and the broader pharmaceutical industry. Investors often view such transactions as a sign of confidence from company leadership, which can affect stock performance and investor relations. Additionally, as CTT operates in the competitive pharmaceutical preparations sector, this move may influence how the company is perceived compared to its peers.

What's Next

The filing does not say what happens next.